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Abstract
Oncogenic Pim family kinases are often overexpressed in human hematopoietic malignancies as well as in solid tumours.
These kinases contribute to tumorigenesis by promoting cell survival and by enhancing resistance against chemotherapy
and radiation therapy. Furthermore, we have recently shown that they increase the metastatic potential of adherent cancer
cells. Here we describe identification of tricyclic benzo[cd]azulenes and their derivatives as effective and selective inhibitors
of Pim kinases. These compounds inhibit Pim autophosphorylation and abrogate the anti-apoptotic effects of Pim kinases.
They also reduce cancer cell motility and suppress proliferation of lymphoblastoid cell lines infected and immortalized by
the Epstein-Barr virus. Thus, these novel Pim-selective inhibitors provide promising compounds for both research and
therapeutic purposes.
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Introduction
Recently there has been enormous progress in developing small
molecule inhibitors against different types of protein kinases,
including multiple compounds targeting Pim kinases [1,2,3]. The
three Pim family members (Pim-1, Pim-2 and Pim-3) form an
evolutionary distinct subgroup of serine/threonine-specific kinases
that structurally belong to the group of calcium/calmodulin-
dependent protein kinases. Pim kinases are highly homologous to
each other and have partially overlapping functions and expres-
sion patterns [4,5]. Unlike most other kinases, Pim kinases are
constitutively kept in an active conformation [6], which is why
their activities correlate well with their expression levels. In
hematopoietic cells, expression of Pim kinases is upregulated by
numerous growth factors and cytokines such as interleukins
[7,8,9]. When overexpressed, Pim kinases are oncogenic and have
been implicated both in hematopoietic malignancies such as
leukemias and lymphomas [10] and in solid tumors such as
prostate, colon, oral, hepatic and pancreatic cancers [11,12].
Pim kinases promote tumorigenesis by supporting cell survival
[13] and by enhancing resistance of cancer cells against
chemotherapy [14] and radiation therapy [15]. At molecular
level, Pim kinases regulate activities of several cellular transcription
factors such as c-Myb [16], NFATc1 [17], STAT5 [18] and the
RUNX family proteins [19]. Also viral factors are affected,
including the Epstein-Barr virus (EBV) nuclear antigen EBNA2
[20] and the Kaposis sarcoma-associated herpesvirus (KSHV)
latency-associated nuclear antigen LANA [21]. In addition, all
Pim family members phosphorylate and thereby inactivate the
pro-apoptotic Bad protein [22,23,24]. All these data may explain
why Pim kinases so efficiently cooperate with Myc family
transcription factors in development of lymphoid or solid tumors.
Even though Myc-overexpressing cells proliferate faster, they are
more prone to apoptosis, so a growth advantage is given to cells
co-overexpressing also the anti-apoptotic Pim kinases. These
conclusions are supported by recent reports [25,26] showing that
Pim-1 synergizes with Myc both to induce advanced prostate
carcinoma and to maintain tumorigenicity of the cancer cells.
Furthermore, we have recently demonstrated that Pim kinases
increase the metastatic potential of adherent cancer cells [27]. For
all these reasons, Pim kinases have become increasingly attractive
targets for cancer therapy. Furthermore, mice lacking activities of
all the three Pim family members show only a fairly mild
phenotype with slightly reduced growth responses [5], so
compounds selectively inhibiting Pim activity are not expected to
have severe adverse side effects.
Here we have analysed the biological effects of new tricyclic
benzo[cd]azulenes, the synthesis methodology of some of which we
have recently described [28,29,30]. We have identified several of
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them as effective and selective inhibitors against Pim family
kinases, and demonstrate that these inhibitors can efficiently
interfere with both biochemical and intracellular activities of Pim
kinases. We have also found evidence that these compounds or
their derivatives could be useful in development of therapies to
treat metastatic tumors and/or to prevent of EBV-induced
lymphomagenesis.
Results
Synthesis of Tricyclic Benzo[cd]azulenes and their Novel
Derivatives
We have reported a facile one-pot method for transformation of
guaiazulene derivatives into tricyclic heptafulvenes 1a–e [28]. The
starting azulenes were treated with an appropriate base to furnish
the new tricyclic benzo[cd]azulene skeleton with a functionalized,
fused six-membered ring (Figure 1). Furthermore, we discovered
that the heptafulvenes 1a–e were prone to oxidative cleavage
when treated with a mild oxidant mCPBA (meta-chloroperoxyben-
zoic acid), yielding the corresponding tricyclic tropones 2a–e
(Figure 1) [28]. In addition, we have recently described the facile
synthesis of tricyclic benzo[cd]azulen-3-ones 3a–c, 4a–c and 5
[29,30] from commercially available guaiazulene. There we had
used acid-catalyzed tautomerization reactions to further transform
benzo[cd]azulen-3-ones 4b–c to regiosiomeric heptafulvenes 1f–g.
When 1f carrying the trifluoromethyl substituent at 4-position was
now modified by oxidation (see Figure 2 below), we obtained a
novel tropone 2f as a regioisomer of 2a.
Benzo[cd]azulenes are Selective Inhibitors against Pim
Family Kinases
Six of the originally synthesized compounds were tested at
10 mM concentration against a panel of 71 different kinases
together with their optimized peptide substrates, as previously
described [31] and screened for residual kinase activities less than
50%. Interestingly, as shown in Table 1, two of the compounds
(1a and 4c) significantly reduced the in vitro activities of Pim family
members, especially those of Pim-1 and Pim-3. 1a was clearly
more selective than 4c, but showed some inhibitory activity also
against PRAK, p38g and some DYRK family members. Also 2a
and 2f were fairly active against Pim-1 and Pim-3 and were even
more selective than 1a, but 2f also efficiently targeted EF2K. By
contrast, 1e and 4b showed hardly any activity in any of the
in vitro kinase assays. Here it should be noted that a screen like this
gives only preliminary estimates on kinase specificity of the
compounds, which is why the results need to be validated by other
means.
Benzo[cd]azulenes Abrogate Anti-apoptotic Effects of
Pim-1 in Cytokine-deprived Myeloid Cells
To determine whether benzo[cd]azulenes can enter the cells and
inhibit intracellular Pim kinase activity, we carried out cell-based
assays with FDCP1 murine myeloid cells that are strictly
dependent on the cytokine interleukin-3 (IL-3) for their growth
and survival. In these assays, we used previously characterized
FDCP1-derived cell lines that had been stably transfected with
either neomycin (FD/Neo) or the 44 kD isoform of Pim-1 (FD/
Pim44) [13]. Since continuous Pim-1 activity significantly prolongs
survival of FDCP1 cells in the absence of IL-3 [23] it was
anticipated that after IL-3 withdrawal, an effective Pim inhibitor
would reduce the survival of FD/Pim44 cells to the level of FD/
Neo cells, but would not have severe cytotoxic effects. To
quantitate the effects of the test compounds on cell viability, we
either measured the metabolic activity of the cells with the MTT
assay or counted Trypan blue-excluding live cells.
When FDCP1 derivatives were cultured for 24 h in the
presence of serum and DMSO, but in the absence of IL-3, FD/
Pim44 cells remained metabolically more active than FD/Neo
cells (Fig. 3A, Ctrl, right panel), as was expected based on our
previous results [23,27]. In the presence of IL-3, there was no such
difference between these two types of cells (Fig. 3A, Ctrl, left
panel). However, when IL-3-deprived cells were treated with
5 mM test compounds dissolved in DMSO, 1a and 2f reduced the
metabolic activity of FD/Pim44 cells significantly to the level of
FD/Neo cells (Fig. 3A, right panel). In the presence of IL-3, 1a
and 2f did not display any general cytotoxicity on FD/Neo cells,
but slightly reduced the metabolic activity of FD/Pim-cells
(Fig. 3A, left panel), suggesting that this stable cell line has become
addicted to continuous expression of Pim-1. By contrast,
compounds 2a, 1e and 4b remained repeatedly ineffective in all
these assays, while 4c displayed strong non-specific cytotoxicity in
both types of cells (Fig. 3A and data not shown). Altogether, these
results indicated that some, but not all of the tested benzo[cd]a-
zulenes are effective cell-permeable Pim kinase inhibitors that can
siginificantly impair the anti-apoptotic effects of Pim-1.
To measure cell viability more directly, we stained cells with
Trypan blue and counted dye-excluding live cells at multiple time-
points after withdrawal of IL-3. As shown in Fig. 3B, FD/Neo cells
treated with DMSO ceased to proliferate and started to die
already after 12 h, while FD/Pim44 cells continued their growth
much longer and were still mostly alive after 72 h. However, when
cells were treated with 5 mM 1a or 2f, the protective effects of
Pim-1 were completely lost and both types of cells died within 72 h
(Fig. 3B and data not shown). These results indicated that results
from the MTT assay on metabolic activity of cells reliably reflect
also cell viability.
Figure 1. Chemical structures of some new and previously synthesized benzo[cd]azulenes.
doi:10.1371/journal.pone.0055409.g001
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To determine the effective concentrations (EC50) of 1a and 2f
that would reduce the viability of cells by 50%, IL-3-deprived FD/
Neo and FD/Pim44 cells were cultured with increasing doses of
the inhibitors and analysed 24 h later by the MTT assay.
Calculation of the EC50 values for 1a or 2f indicated that they
were nearly similar in both FD/Neo (5.2 and 6.9 mM) and FD/
Pim44 (3.2 and 6.1 mM) cell lines, respectively (Fig. 3C–D).
Benzo[cd]azulenes Prevent Cancer Cell Migration
We have recently shown that Pim family kinases enhancemotility
of adherent cancer cells [27]. Therefore, we wanted to analyse the
ability of 1a to prevent migration of PC-3 prostate cancer cells as
well as UT-SCC-12A head and neck squamocellular carcinoma
cells. For this purpose, confluent cells were treated with either
DMSO or 10 mM 1a. Two hours later, wounds were scratched
across the cell monolayer and pictures were taken at distinct time-
points to follow up the healing process. Results from these scratch
wound assays clearly indicated that 1a decreases themotility of both
PC-3 cells (Fig. 4A–B, Movies S1, S2) and UT-SCC-12A cells
(Fig. 4E–F). By contrast,metabolic activities of both types of cells and
cellular expression of Pim family members were not significantly
affected by 1a, as measured by theMTT assay (Fig. 4C and data not
shown) and by Western blotting (Fig. 4D and data not shown),
respectively. Furthermore, these results were well in line with those
previously obtained using the Pim-selective inhibitorDHPCC-9 or
Pim-specific RNA interference reagents [27], suggesting that the
effects of also benzo[cd]azulenes are specifically targeted against
intracellular Pim kinase activity.
Benzo[cd]azulenes Prevent Proliferation of
Lymphoblastoid Cell Lines
We have previously demonstrated that Epstein-Barr virus (EBV)
upregulates expression and activity of Pim family proteins in the
hosting B-cells and that Pim kinases in turn stimulate the
transactivation activity of the EBV nuclear antigen 2 (EBNA2)
[20]. To determine whether maintenance of high Pim activity is
essential for proliferation of EBV-infected and immortalized
lymphoblastoid cell lines (LCLs), we picked up two such cell lines,
and propagated them in the presence of DMSO or 10 mM 1a.
Cells were grown for up to 9 days and kept in an optimal density
by adding more medium together with either DMSO or 1a. When
live cells excluding Trypan blue were counted on alternate days,
the DMSO-treated control cells steadily continued their prolifer-
ation; while the cells treated with 1a slowed down or even
completely stopped growth, but did not die out, either (Fig. 5).
Similar effects by 1a were obtained, whether the medium was
completely replaced during the experiment or whether condi-
tioned medium was used (data not shown).
Figure 2. Synthetic steps in the preparation of new benzo[cd]azulenes.
doi:10.1371/journal.pone.0055409.g002
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Synthesis of Additional Benzo[cd]azulene Derivatives to
Identify more Effective Pim Inhibitors
Based on the promising results on Pim kinase inhibition in
multiple cell-based assays, we embarked on further modification of
the azulenes, heptafulvenes and tropones presented in Figure 1.
The aim was to develop derivatives that would be even more
potent as Pim kinase inhibitors than the original benzo[cd]azulene
compounds.
Tropone 2a [28] was used as a key intermediate, since it was
easily accessible in high yield (82%) from the parent heptafulvene
1a that was shown to be an effective and selective Pim kinase
inhibitor. In addition, the tropones were generally found to be
chemically more stable than the corresponding heptafulvenes. The
exocyclic double bond was restored in a single transformation,
when 2a was subjected to the Knoevenagel condensation with
malononitrile in a reaction catalysed by ammonium acetate to give
highly conjugated dicyanoheptafulvene 6a (analogous two-step
synthesis via ethoxytropylium fluoroborate [32]) in 45% yield
(MeOH, reflux, 2–3 d, Figure 2). This crystalline product has a
good chemical stability in aqueous solutions. Since demethylation
of the methoxy group on tropones 2a and 2f under standard
conditions (BBr3, 2–4 equiv., CH2Cl2, rt, 2–8 h) was found to be
unsuccessful, the free phenol analogue 2c (Figure 1) [27] was
synthesized and subjected to the Knoevenagel condensation
Table 1. Selectivity of benzo[cd]azulenes against
recombinant kinases.
Kinase Residual activity (%)
Compound 1a 1e 2a 2f 4b 4c
ERK1 114 114 126 111 121 86
ERK2 109 91 104 94 109 108
JNK1 97 84 86 96 109 73
JNK2 89 87 86 95 104 83
p38a MAPK 98 94 91 100 123 95
P38b MAPK 93 93 96 102 110 99
p38g MAPK 62 117 90 75 106 113
p38s MAPK 90 105 98 84 93 95
ERK8 94 103 101 83 101 55
GSK3b 128 97 97 112 105 99
CDK2-Cyclin A 85 96 87 91 78 87
DYRK1A 56 92 82 97 107 91
DYRK2 99 80 104 84 88 67
DYRK3 63 90 90 90 89 55
SRPK1 90 99 92 100 113 76
HIPK2 76 83 68 83 87 52
RSK1 92 104 87 104 100 91
RSK2 100 76 110 89 106 64
PDK1 68 101 105 93 69 113
PKBa 90 97 102 101 115 92
PKBb 150 78 83 161 157 54
SGK1 103 105 101 78 109 81
S6K1 92 90 73 96 115 77
PKA 129 106 97 102 98 107
ROCK 2 94 96 95 97 100 93
PRK2 100 106 100 92 111 116
PKCa 72 86 72 99 101 80
PKC zeta 107 98 97 87 100 66
MSK1 108 108 101 102 109 79
PKD1 107 93 103 94 95 97
MNK1 96 101 96 77 103 103
MNK2 67 74 78 65 86 80
MAPKAP-K2 81 87 80 83 100 58
PRAK* 56 69 72 89 93 42
CAMK1 78 76 102 97 100 75
SmMLCK 73 92 74 78 89 90
PHK 94 99 118 100 105 100
CHK1 128 98 87 95 101 128
CHK2* 88 90 90 106 114 35
AMPK 95 101 94 96 97 99
MARK3 110 100 93 99 111 105
BRSK2 69 196 294 85 80 126
MELK 90 102 106 102 98 63
PIM-1* 42 86 63 58 84 50
PIM-2 72 110 103 95 95 83
PIM-3* 30 80 56 66 82 24
CK1 108 114 116 114 108 101
Table 1. Cont.
Kinase Residual activity (%)
Compound 1a 1e 2a 2f 4b 4c
CK2 90 101 94 103 107 92
MKK1 81 77 70 85 88 78
MST2 109 97 114 114 108 94
PAK4 82 90 101 92 86 83
PAK5 82 82 77 90 99 80
PAK6 110 101 109 96 111 99
MST4 95 104 85 99 77 69
Src 93 90 99 104 104 102
Lck 91 89 79 88 94 77
CSK 94 79 78 98 97 75
FGF-R1 100 105 110 106 100 51
IRR 78 93 87 74 94 84
EPH A2 105 100 99 96 90 96
SYK 111 123 132 128 118 65
YES1 116 99 91 82 96 54
EF2K* 73 137 116 39 62 129
CAMKKb 100 103 98 105 95 108
NEK2a 98 118 131 96 99 69
NEK6 122 105 141 101 110 73
IKKb 103 112 105 108 96 94
PLK1 99 93 117 93 100 60
PLK1 (okadaic
acid)
88 80 71 82 82 59
IKKe 85 85 83 105 105 59
TBK1 98 92 106 104 103 99
Kinase assays were carried out at 10 mM concentrations of benzo[cd]azulenes
dissolved in DMSO. Residual activity of the kinases is shown.
*marks for residual activity #50%.
doi:10.1371/journal.pone.0055409.t001
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(malononitrile, MeOH, reflux, 4 d) to give the phenolic dinitrile
6b (Figure 2). In the presence of hydrazine monohydrate (MeOH,
reflux, 20 h), the carbonyl group of 2a was transformed into
hydrazide product 7 (Figure 2), which was isolated as an
inseparable mixture of two diastereomers (Z/E, 1H NMR).
The carbonyl group of 2a was transformed into the oxime
functionality by treating it with hydroxylamine hydrochloride in
the presence of base in a mixture of isopropanol–water (3:1) for a
prolonged time (80uC, 5 d, Figure 2). Two stereoisomers were
separated by a careful column chromatography on silica gel
followed by recrystallization from ethyl acetate/n–hexane to give
pure Z and E isomers (NMR, NOE assignment) of oximes 8a
(29%, orange needles) and 8b (42%, yellow needles). No 2-
aminotropone derivatives 9 were isolated as reported previously
for the tropone itself to produce a mixture of products under the
same reaction conditions [33].
In the presence of phosphonium ylides the a,ß-unsaturated
ketone moiety of tropone 2a was found to undergo 1,4-conjugate
addition reaction instead of the expected Wittig reaction. A related
reaction type has been reported previously [34,35]. The ylide 10
[36] was allowed to react with 2a at low temperature (–78uC) to
give one main product 11 in 38% yield after aqueous acidic
work-up and chromatographic purification. Extensive 2D NMR
(HMBC, HSQC, and NOESY) analysis revealed that 11 had an
unexpected structure of a quaternary aldehyde with a non-planar
junction between the fused seven and five-membered rings
(Figure 2).
Catalytic hydrogenation of 2a gave one main product after
chromatographic isolation. Instead of reduction of the double
bond in the seven member ring system reported for 3,4-fused
benztropone [33], it was found that the double bond in the 5-
membered ring of 2a was highly susceptible to catalytic
hydrogenation, when the reaction conditions were carefully
controlled (Figure 2, H2, 10% Pd/C, EtOAc, 0uC, 50 min). The
racemic non-planar compound 12 was obtained in 40% yield. The
C=C double-bond in a five-member ring showed regioselectivity
towards oxidation, when tropone 2a was treated with excess of
mCPBA for prolonged time (3 eq, rt, 5 d) giving the racemic
epoxide 13 as a main product in 42% yield after column
chromatography. The oxirane ring in 13 was prone to acid-
catalyzed ring opening (perchloric acid) to give trans-diol 14a in
high yield (89% after column chromatography). The correspond-
ing cis-diol 14b was synthesized directly from the alkene 2a by
using catalytic amount of osmium tetroxide (OsO4) and N-
Figure 3. Benzo[cd]azulenes inhibit Pim-1-dependent cell survival. (A) FDCP1 cell lines stably expressing neomycin (FD/Neo) or Pim-1 (FD/
Pim44) were cultured for 24 h with or without IL-3 in the presence of DMSO or 5 mM inhibitors, after which cell viability was analyzed by the MTT
assay. Graph represents means and standard deviations from two independent experiments with duplicate samples. Statistically significant
differences between inhibitor-treated cells as compared to DMSO-treated control cells have been marked with asterisks. (B) Cells grown in the
absence of IL-3 were stained with Trypan blue and live cells were counted at the indicated time-points. Points represent means and standard
deviations from triplicate determinations from one of two similar experiments. (C–D) Cells were cultured for 24 h without IL-3 in the presence of
increasing concentrations of either 1a (C) or 2f (D). Cell viability was analysed by the MTT assay and EC50 values were determined. Points represent
means and standard deviations from three independent experiments with duplicate samples.
doi:10.1371/journal.pone.0055409.g003
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methylmorpholine N-oxide (NMO) as a co-oxidant. Both 14a and
14b showed improved solubility in protic solvents and were
colourless as compared to the previously synthesized strongly
coloured tropones (yellow/orange).
We had recently reported a tautomerization reaction that
proceeds via isomerization of p-bonds across the azulene moieties
of tricyclic benzo[cd]azulen-3-ones 4a–c synthesized from the
parent 4,5-dihydrobenzo[cd]azulen-3-ones 3a–c [29]. This effi-
cient synthetic route had produced heptafulvenes 1f and 1g (Fig. 1)
with the regioisomeric substitution pattern on the aromatic six-
membered ring. Using mCPBA in CH2Cl2 at 0uC, we were now
able to oxidize the heptafulvene derivative 1f [29] to obtain the
novel tropone 2f in high yield (85%) (Figure 1, Figure 2). By
contrast, isolation of the phenol tautomer 15 of benzo[cd]azulen-3-
one 4c was not possible due to reverse nature of the tautomer-
ization reaction, so phenolic products could not be synthesized.
Demethylation of the aryl methyl ethers on tropones 2a and 2f to
phenolic products with standard reagent (BBr3) was also ineffi-
cient. However, to overcome this problem, a cleavable phenolic
tautomer could be trapped as a silyl enol ether. This strategy was
demonstrated in the efficient two-step synthesis, where the phenol
tautomer was generated first in situ (HCl, cat., THF, rt, 20 min)
and, after deprotonation, derivatized by silylation (NaH, 5 equiv
and TBDMSCl 2.5 equiv, rt, 2–3 h) to give 16 in high 84% yield
(Figure 2). This allowed the mCPBA oxidation of the exo-double
bond of heptafulvene 16, followed by a removal of the TBDMS-
protection group by a 1.0 M solution of TBAF (tetrabutylammo-
nium fluoride) in THF (1.2 equiv, THF, rt, 2 h) to finally give the
troponoyl phenol 17 (Figure 1, Figure 2) as a regioisomer of the
benzo[cd]azulene 2c.
Some Benzo[cd]azulene Derivatives are Effective as Pim
Inhibitors
To determine the efficacy of previously or newly synthesized
compounds, we performed in vitro kinase assays with bacterially
produced human Pim-1 protein and measured its residual activity
in the presence of 10 mM concentrations of the compounds. The
previously tested compounds 1a, 1e, 2a, 2f, 4b and 4c were used
as positive controls to succesfully confirm that the newly obtained
results shown in Table 2 were within the same range as those
shown in Table 1. By contrast, the other benzo[cd]azulenes and
their derivatives tested inhibited the autophosphorylation activity
of Pim-1 to a variable extent. Several of them were as effective as
the parental ones, but some were even more potent. The most
striking results were obtained with 2c, which repeatedly reduced
the autophosphorylation activity of Pim-1 by up to 89%.
Figure 4. Benzo[cd]azulene 1a decreases cancer cell migration without affecting cell viability or Pim protein levels. (A–B) PC-3 cells
were cultured on 24-well plates, treated with either 0.1% DMSO (Ctrl) or 10 mM 1a and scratched with a sterile 200 mL pipette tip. Pictures were taken
at indicated time-points and analyzed. Shown are representative pictures from each time-point. The graph represents means and standard deviations
from triplicate samples. (C) MTT assay was used to study the effects of DMSO and 1a on PC-3 cell viability. Shown are means and standard deviations
from duplicate samples from one of two similar experiments. (D) Western blotting with antibodies specific for each Pim family member was carried
out with samples of PC-3 cells that had been treated for 24 h with either 0.1% DMSO (Ctrl) or 10 mM 1a. Shown is a representative picture from two
independent experiments. (E–F) Wound healing assays were performed with the UT-SCC-12A cell line similarly to the PC-3 cell line. Shown are
representative pictures from indicated time-points. The graph represents means and standard deviations from triplicate samples.
doi:10.1371/journal.pone.0055409.g004
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To analyse the properties of the benzo[cd]azulene derivatives
also in cell-based assays, FD/Neo and FD/Pim44 cells were
cultured for 24 h in the presence of serum, but in the absence of
IL-3. When cells were treated with 5 mM test compounds dissolved
in DMSO, most of them did not have any effects on viability of
either FD/Neo or FD/Pim44 cells or reduced it in both cell lines
to a similar extent (Table 2). Even though 2c very efficiently
inhibited the in vitro kinase activity of Pim-1, in cell-based assays it
was far less potent with signs of some cytotoxicity. Indeed, only
one of the newly synthesized compounds, 6a, displayed similar
properties as 1a and 2f and efficiently impaired the pro-survival
advantage of Pim-1 overexpression in FD/Pim44 cells. However,
6a also slightly affected the Neo-expressing control cells at the
5 mM concentration.
Structure–activity Relationships of Novel
Benzo[cd]azulenes
The structures and in vitro activities of compounds used for the
structure-activity relationship are given in Figure 1, Figure 2 and
Tables 1 and 2. In the heptafulvenic compound series with the
isopropylidene substituent on the 7-membered ring, 1a with the
trifluoromethyl and methoxy substituents on 3- and 4-positions,
respectively, displayed promising inhibition with residual Pim-1
kinase activity of 43%. Its regioisomer 1f was nearly as active
(residual activity 46%). The importance of the trifluoromethyl
substituent was demonstrated by replacing it with a methyl group
in 1g, since this resulted in a complete loss of inhibitory activity
(residual activity 105%). In cell-based assays, compound 1a
efficiently reduced Pim-1-dependent survival of FD/Pim44 cells
(cell viability 65%) without marked effects on the FD/Neo control
cells, and was therefore considered as an effective cell-permeable
Pim-1-selective inhibitor. By contrast, the regioisomeric heptaful-
vene 1f was completely ineffective in these assays and rather
showed some signs of off-target cytotoxicity (FD/Neo 74%, FD/
Pim44 97%).
The 4-phenol analog 1c was found to be highly efficient in vitro
with low residual Pim-1 activity (29%). However, since it showed
chemical instability, it was excluded from cell-based assays. When
the 4-hydroxy functionality of 1c was replaced with a phenyl ring
in 1e, the residual Pim-1 activity was increased to 59% and no
potency for this compound was observed within cells.
The tropones 2a and 2f were slightly less potent than the
parental heptafulvenes 1a and 1f, with 74% and 58% residual
in vitro activities of Pim-1, respectively. In cell-based assays 2a was
observed to pose some non-specific cytotoxicity affecting both FD/
Neo and FD/Pim44 cells (80% and 81%, respectively). However,
its regioisomer 2f appeared to be as potent as 1a and efficiently
impaired the Pim-1-dependent survival of FD/Pim44 cells (69%)
without any adverse effects on FD/Neo cells. When the
trifluoromethyl substituent of 2a was replaced with an ethox-
ycarbonyl group in 2d, the kinase inhibitory activity was again
completely lost (residual activity 98%), which was in line with the
results on its heptafulvenic methyl analogue 1g.
Tropone 2c with a phenolic residue at 4-position was the most
potent inhibitory compound in vitro with residual Pim-1 activity of
only 11%, while its regioisomer 16 was not that efficient (residual
activity 65%). Yet in cell-based assays 2c was disappointingly far
less potent than expected with some signs of off-target cytotoxicity
(FD/Neo 85%, FD/Pim44 83%).
The five-member ring of 2a was subjected to further
modifications. This was possible through regioselective oxidation
that yielded epoxide 13 with slightly stronger in vitro inhibition
potential (residual activity 65%) than with the parental 2a (residual
activity 74%). The cis- and trans–diols 14b and 14a also had
slightly better in vitro activities against Pim-1 (residual activities
55% and 69%, respectively). It should be mentioned here that
both of these compounds showed signs of improved solubility into
protic solvents (data not shown).
When the C=C double bond in the five-member ring of 2a was
reduced by catalytic hydrogenation, the non-planar alkane 12 was
regioselectively obtained as a single compound. This compound
did not have any effects against Pim-1 (residual activity 107%),
suggesting that the planarity of the five-member ring is important
for the observed inhibitory effects of the other compounds. While
the quaternary aldehyde 11 displayed promising in vitro inhibition
of Pim-1 (residual activity 34%), in cell-based assays it showed
obvious signs of non-specific cytotoxicity (FD/Neo, FD/Pim44,
both 64%).
The troponyl oxygen atoms on the 8-position of tropones 2a
and 2c were also subjected to further modifications. The
malononitrile groups in 6a and 6b restored the heptafulvenic
structure and resulted in moderate to effective in vitro inhibition of
Pim-1 (residual activities 60% and 41%, respectively). While the
dicyanoheptafulvene 6a reduced the survival of FD/Pim44 cells
surprisingly well (viability 61%), it also turned out to be slightly
cytotoxic for FD/Neo cells (78%), suggesting that such effective
derivatives should be used at lower concentrations. By contrast,
the phenolic derivative 6b showed no efficacy in cell-based assays
(FD/Pim44 93%), although in vitro it had been more potent than
6a.
When the oximes 8a and 8b were transformed from the ketone
carbonyl of 2a and assayed separately as pure Z- and E-isomers,
fairly mild inhibition of Pim-1 was observed in vitro (residual
activities 71% and 82%, respectively). Similarly, the hydrazide
derivative 7 showed only moderate inhibition (residual activity of
64%), as did also compound 5 representing the group of
heterocyclic azulene derivatives (residual activity 59%).
In the series of benzo[cd]azulen-3-ones with a ketone carbonyl
on the 3-position of the 6-membered ring, 3c with a trifluor-
omethyl group was more effective in vitro against Pim-1 than 3b
with the methyl substituent (residual activities 74% and 92%,
respectively). The subsequently dehydrated 4-methyl analog 4b
Figure 5. Benzo[cd]azulenes prevent proliferation of lympho-
blastoid cell lines. LCL cell lines were cultured for up to 9 days in
optimal density on 6-well plates and treated with either 0.1% DMSO
(Ctrl) or 10 mM 1a. Viable cells were counted by Trypan blue staining.
Shown are means and standard deviations from two parallel samples in
one representative experiment.
doi:10.1371/journal.pone.0055409.g005
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Table 2. Efficacy of benzo[cd]azulenes as Pim-1 inhibitors in vitro and in cell-based assays.
Structure Compound code, reference
Residual Pim-1
activity in vitro
Residual viability of
FD/Neo cells
Residual viability of
FD/Pim44 cells
1a1 43 94 65
1c1 29 N.D. N.D.
1e1 59 100 96
1f2 46 74 97
1g2 105 N.D. N.D.
6a 60 78 61
6b 41 87 93
2a1 74 80 81
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Table 2. Cont.
Structure Compound code, reference
Residual Pim-1
activity in vitro
Residual viability of
FD/Neo cells
Residual viability of
FD/Pim44 cells
2c1 11 85 83
2d1 98 N.D. N.D.
2f 58 123 69
11 34 64 64
12 107 N.D. N.D.
13 65 N.D. N.D.
14a 69 N.D. N.D.
14b 55 N.D. N.D.
17 65 N.D. N.D.
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Table 2. Cont.
Structure Compound code, reference
Residual Pim-1
activity in vitro
Residual viability of
FD/Neo cells
Residual viability of
FD/Pim44 cells
7 64 N.D. N.D.
8a 71 87 81
8b 82 N.D. N.D.
3b2 92 N.D. N.D.
3c2 74 N.D. N.D.
4a2 62 N.D. N.D.
4b2 91 N.D. N.D.
4c2 51 6 3
53 59 N.D. N.D.
1Prepared according to [28].
2Prepared according to [29].
3Prepared according to [30].
Residual in vitro activity of Pim-1 was determined in the presence of 10 mM concentrations of benzo[cd]azulenes dissolved in DMSO. Data were calculated as the
percentage of Pim-1 autophosphorylation as compared with DMSO-treated controls. Residual cellular viabilities were determined by the MTT assay from FD/Neo and
FD/Pim44 cells that had been cultured for 24 h without IL-3 in the presence of 0.1% DMSO or 5 mM inhibitors. Data were calculated as the percentage of viable cells in
treated cultures as compared with DMSO-treated controls from at least two independent experiments with duplicate samples. N.D. means that viability was not
determined.
doi:10.1371/journal.pone.0055409.t002
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was also found to be inactive (residual activity 91%), but 4a with
no substituent at 4-position had moderate residual Pim-1 activity
(residual activity 62%). The 4-trifluoromethyl analog 4c displayed
moderate in vitro activity against Pim-1, but was surprisingly
effective when tested against Pim-3 (residual activities 51% and
24%, respectively). However, in the cell-based assays 4c dramat-
ically reduced the viability of both cell lines (FD/Neo 6%, FD/
Pim44 3%), possibly due to its enhanced reactivity with various
nucleophiles (data not shown) and/or its lack of target selectivity,
as shown in Table 1.
Discussion
Pim kinases have recently emerged as promising targets for
therapy against both hematological malignancies and solid tumors.
Therefore, there is increasing interest towards identification of
potent and selective small molecule compounds inhibiting their
activity. We have previously described synthesis of tricyclic
benzo[cd]azulenes [28,29,30] and have now recognized that they
possess kinase-inhibitory activity. Moreover, we have observed
that under in vitro conditions, some of them show striking
selectivity against Pim family kinases as compared with the 68
other protein kinases analysed. They are clearly more effective
towards Pim-1 and Pim-3 than Pim-2, which correlates well with
observations on several other compounds targeting the Pim family
kinases [12,27]. Since the amino acid sequences as well as
structures of Pim family kinases are highly related to each other,
their different sensitivities to inhibitory compounds remain to be
explained.
The in vitro inhibitory activities of most benzo[cd]azulenes are
not as impressive as with some other reported ATP-competitive
compounds such as the pyrrolocarbazole DHPCC-9, which
inhibits activities of Pim kinases already at low nanomolar
concentrations [37]. Yet it is intriguing to notice that both types
of compounds are equally efficient in cell-based assays, since both
in our previous study [27] and in this study we have demonstrated
them to abrogate the anti-apoptotic effects of Pim-1 in cytokine-
deprived FDCP1 myeloid cells at low micromolar concentrations
without any major signs of general cytotoxicity. Thus, it is possible
that benzo[cd]azulenes are more permeable across cell membranes
due to the planar but not ATP-mimetic lipophilic ring structure,
less reactive with serum and other growth medium or intracellular
constituents or otherwise reach their targets more efficiently to
compensate for their lower in vitro activities. Since different types of
Pim inhibitors have fairly distinct spectra of target specificities and
since their inhibitory effects can be mimicked by using Pim-specific
RNA interference reagents [27], it is highly likely that the observed
effects of also benzo[cd]azulenes are due to their ability to
selectively interfere with Pim activities.
Based on this study, the most potent benzo[cd]azulene structures
to inhibit intracellular anti-apoptotic activities of Pim kinases were
the heptafulvene 1a and the tropone 2f, with low micromolar
EC50 values. Further functional analyses indicated that 1a-like
benzo[cd]azulenes significantly reduce migration of adherent
cancer cells derived from either prostate or squamocellular
carcinomas. By contrast, such compounds do not significantly
affect metabolic activity or viability of cancer cells or their levels of
Pim protein expression. These results suggest that benzo[cd]azu-
lenes or their derivatives have great potential in development of
drugs against invasive tumors overexpressing Pim family members.
The ability of the benzo[cd]azulenes compounds such as 1a to
inhibit proliferation of EBV-transformed lymphoblastoid cell lines
is also of interest, and suggests that these cells have become
addicted to the EBV-induced expression of Pim kinases. Most
people get infected with EBV before reaching adulthood, although
usually the infection does not cause any major harm. However,
since EBV remains latent in B-lymphocytes, it can reactivate itself
later in immunocompromised individuals such as transplantation
patients and cause aggressive lymphoproliferation and lymphoid
tumours [38]. Therefore there is a clear demand to develop new,
better tolerated drugs for the immunocompromised patients that
are unusually sensitive to current chemotherapies, and need
protection against EBV only transiently. Thus, the novel Pim-
selective inhibitors or their derivatives may provide useful
compounds for developing new drugs to restrict the effects of
EBV in sensitized patients.
For this study, we have synthesized several novel benzo[cd]a-
zulene structures and carried our structure-activity analyses to
reveal the key features of both the known and novel compounds.
These analyses have revealed that the CF3-substituent on the
phenyl ring plays an essential role in effective inhibition of Pim-1
kinase. This was demonstrated with compounds bearing alterna-
tive substituents, such as those found in methyl and ethoxycarbo-
nyl analogs 1g and 2d, both being inactive compounds. The
presence of phenolic hydroxyl group on the six-membered ring of
benzo[cd]azulenes was also important. Indeed, tropone 2c and
heptafulvenes 1c and 6b, bearing a phenol as a common
structural feature at 4-position, showed efficient in vitro inhibitory
activities against Pim-1. By contrast, the regioisomeric tropone 17
showed only modest efficiency as compared to the above-
mentioned compounds.
Intriguingly, the in vitro activities of benzo[cd]azulenes did not
always correlate with their efficacy in cell-based assays. While the
tropone 2c very efficiently inhibited Pim-1 activity in vitro, it was
less potent in cells and also showed some signs of cytotoxicity. By
contrast, 2f displayed only mild effects in vitro, but was still almost
as effective as 1a in cell-based assays. The same fashion was seen
with the dicyano-derived compound 6a, which demonstrated
good chemical stability over ‘‘normal’’ methyl-substituted hepta-
fulvenes and which was the third most effective Pim-inhibitory
compound in the cell-based assays. Thus, differences in solubility,
stability and selectivity in addition to cell permeability may affect
the biological outcomes, which are hard to predict just based on
structure or even in vitro results. Ongoing optimization of
additional benzo[cd]azulene derivatives is expected to further
improve their efficacy as Pim-selective kinase inhibitors and anti-
tumor drug candidates.
Conclusions
In this study, we have identified and functionally characterized
tricyclic benzo[cd]azulenes as new compounds capable of inhib-
iting protein kinase activity. Many of the described compounds are
structurally novel, as also their synthesis routes, and several of
them show selectivity towards Pim family kinases. While such
benzo[cd]azulenes effectively inhibit in vitro autophosphorylation of
Pim kinases, they are also able to enter the cells and efficiently
impair intracellular anti-apoptotic and other activities of Pim
kinases, as most strikingly demonstrated by the loss of Pim-
dependent survival of cytokine-deprived myeloid cells. Further-
more, the Pim-inhibitory benzo[cd]azulenes significantly slow
down migration of adherent cancer cells derived from either
prostate or squamocellular carcinomas. In addition, they efficiently
inhibit proliferation of lymphoblastoid cell lines (LCLs) that have
been infected and immortalized by the Epstein-Barr virus. Taken
together, benzo[cd]azulenes and their derivatives provide a new
group of compounds that may be used not only as effective and
selective research tools to investigate Pim functions, but also as
promising scaffolds in development of small molecule therapies
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against Pim-overexpressing invasive tumors and other tumorigenic
disorders.
Materials and Methods
Kinase Selectivity Assays
The selectivity of the compounds 1a, 1e, 2a, 2f, 4b and 4c was
tested against 71 kinases on a commercial basis in a kinase
platform at the Division of Signal Transduction Therapy,
University of Dundee, UK. Assays were run at ATP concentra-
tions, which were close to the Km value of each kinase. One
concentration (10 mM) of the compounds was used with each
kinase with duplicate wells [30]. The data is expressed as the
percentage of residual kinase activity. Due to the two-point
inhibition data, the uncertainty values were large and this is why
only residual activity ,50% was considered significant.
In vitro Phosphorylation Assays
Wild-type human Pim-1 protein produced in bacteria as a
GST-fusion protein was purifed with glutathione sepharose beads
(GE Healthcare) and cleaved with PreScission protease (GE
Healthcare) according to manufacturers instructions. For each
kinase reaction, 0.5–1 mg of Pim-1 protein was preincubated for
10 min with DMSO-dissolved compounds at a final inhibitor
concentration of 10 mM. DMSO alone was used in control
reactions. Radioactive kinase reactions were performed in a buffer
containing 15 mM Pipes (pH 7.4), 5.5 mM MnCl2, and 15 mM
ATP with a specific activity of 150 mCi/mL for 15 min at 30uC.
Reactions were stopped by boiling in Laemmli sample buffer for
5 min at 95uC. Phosphorylated proteins were resolved in 10%
SDS-PAGE and stained with Coomassie blue (PAGE-BLUE,
Fermentas) to confirm equal loading. Radioactivity of the samples
was analysed by autoradiography and quantitated by the MCID
M5+ Image Analyzer (InterFocus, UK). Data were calculated as
the percentage of residual Pim-1 kinase activity as compared with
DMSO-treated controls.
Cell Lines and Culture Conditions
The murine IL-3-dependent myeloid FDCP1 cell lines [13], the
lymphoblastoid cell lines (LCLs) infected and immortalized by
Epstein-Barr virus (EBV) [20] and the head and neck squamocel-
lular carcinoma cell line UT-SCC-12A [15] have all been
described previously. The human androgen-independent prostate
epithelial adenocarcinoma cell line PC-3 was obtained from the
American Type Culture Collection. FDCP-1, LCL and PC-3 cells
were grown in RPMI-1640 medium and UT-SCC-12A cells were
grown in DMEM medium. All media were supplemented with
10% fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin
and 100 mg/mL streptomycin. In addition, 1% non-essential
amino acids were added to UT-SCC-12A cell cultures and 10%
WEHI-conditioned medium was used as the source of IL-3 for
FDCP1 cell lines.
Cell Viability Assays
For viability assays, FDCP1 cell lines were seeded onto 96-well
plates at 26105 cells/mL and grown with or without IL-3 for
different time-points. Varying concentrations of the test com-
pounds dissolved in DMSO were added to the cellular culture
medium, while 0.1% DMSO was added to control cell samples.
Cells were incubated for 24 h, after which their viabilities were
analyzed either by MTT assays or Trypan blue staining, as
described previously [27].
Lymphoblastoid cell lines (LCLs) cells were seeded onto 12-well
plates at either 1 or 36105 live cells/mL. Cells were then treated
with 10 mM test compounds or 0.1% DMSO. For each treatment,
there were two parallel samples. Cell density was kept under 106/
mL over the whole experiment, and additional medium and
DMSO or test compounds were added when density was getting
higher. The amounts of live cells excluding Trypan blue were
counted on alternate days.
Western Blotting
Expression levels of 50 mg aliquots of proteins were measured
from cell pellets by Western blotting as described previously [27]
using the following antibodies: anti-Pim-1 (1:10000 dilution of
EP2645Y; Abcam), anti-Pim-2 (1:1000 of D1D2; Cell Signaling
Technology), anti-Pim-3 (1:1000 of D17C9; Cell Signaling
Technology) and anti-GAPDH (1:20000; Sigma-Aldrich) antibod-
ies.
Wound Healing Assays
Cells were plated on 24-well plates, allowed to attach for 24 h,
and then treated with either 0.1% DMSO or 10 mM DMSO-
dissolved test compounds. Two hours later, scratch wounds were
made with a sterile 200 mL pipette tip. Photographs were taken
using the Zeiss Stereo Lumar-V12 microscope with the AxioVision
Rel.4.8 software with 35-fold enlargement. Wounds were outlined
and the wound areas were measured by the ImageJ software
(Wayne Rasband, NIH, USA).
Statistical Analyses
Microsoft Excel was used to calculate wound healing percent-
ages and statistical significance of data (t-test: paired two samples
for means). Results were interpreted as highly significant***
(p,0.001), significant** (p,0.01), weakly significant* (p,0.05) or
not significantns (p.0.05). IC50 values of test compounds in
FDCP-1 cells were determined using nonlinear regression fitting
with the GraphPad Prism v.5.0. Error bars in all graphs represent
SD values.
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